A 2026 study published in the journal Obesity reports that dapagliflozin, a diabetes medicine in the SGLT2 inhibitor class, reduced liver fat in people with type 2 diabetes - and the reduction was independent of weight loss. That last clause is the part worth slowing down for, because it separates the drug’s direct effect on the liver from the indirect benefit that comes simply from losing weight.
Dapagliflozin works by making the kidneys excrete more glucose in the urine, which lowers blood sugar and, as a side effect, sheds calories. Most of its benefit was assumed to run through that weight and glucose effect. The 2026 finding challenges that simple story: even holding weight change out of the equation, the drug still moved liver fat. That points at a liver-specific mechanism, not just a weight mechanism.
Why a diabetes drug shows up on a food site
The reason this matters here is that MASLD and type 2 diabetes are two names for the same metabolic disease in different organs, and the drugs that treat one keep reporting effects on the other. Dapagliflozin is a prescription medicine, full stop - it is not a food, and this site does not recommend medicines. But the finding is a useful correction to the idea that only weight loss moves liver fat: the liver has its own metabolic levers, and they can be pulled directly.
That correction points back at the plate. If a drug can reduce liver fat through a weight-independent route, then the food pattern - which works through several routes at once, weight loss among them - is not a weaker fallback but the same set of levers pulled every day without a prescription. The study does not make diet optional; it makes the direct-metabolic case for why diet and medicine are complements.
The food side of the same levers
The database gives the per-food version of the direct-metabolic argument. The Recommended column lowers the saturated share and the added sugar that drive liver fat through de novo lipogenesis, and it raises the fiber and unsaturated fat that push the other direction. Fatty fish, legumes, whole grains, olive oil, and vegetables are the pattern; salmon sits around 1.3 grams of saturated fat per 100 grams with omega-3s, and rolled oats carry about 10 grams of fiber per 100 grams.
The honest note is that the food pattern and a medicine like dapagliflozin are not competitors. A clinician manages the prescription and the labs; the database manages the plate; and the 2026 finding simply shows both are pulling the same lever from different directions. That is the correct frame, and it is the one this site keeps.
How our editorial team read this
Drug stories are where we are most careful, because a wrong read travels fast. Our data editor verified the study, the class, and the weight-independence claim against the published report, and we kept the medicine where it belongs - with a clinician. We did not present dapagliflozin as a fatty-liver treatment a reader should seek, and we did not frame the diet as a substitute for prescribed diabetes care.
What we did do is use the finding to sharpen the food message: liver fat responds to more than the scale, and the pattern that manages it directly is already in the Recommended column. The reader-facing line is simple - the medicine is the clinician’s decision, the plate is the daily lever, and the study connects the two.
The practical takeaway
For someone with type 2 diabetes and fatty liver, the dapagliflozin finding is a reason to keep both tools sharp: the prescription under a clinician’s watch, and the Recommended column under the reader’s own control. The database covers the plate; the doctor covers the medicine; the liver responds to both.